HealthcareServices

Chlamydia Market to Reach $4.49 Billion by 2029, Growing at a CAGR of 8.6%

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Chlamydia Industry By The Forecast Year 2029?

The chlamydia market has experienced significant growth in recent years. It is anticipated to expand from $2.97 billion in 2024 to $3.23 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.7%. This past growth can be attributed to factors such as the expansion of sexual health education programs, an increased demand for rapid diagnostic tests, the rising need for cost-effective and scalable STI diagnostics, the advancement of telemedicine, and a greater emphasis on precision medicine.

The chlamydia market size is projected to experience substantial expansion over the upcoming years. Its value is anticipated to reach $4.49 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.6%. This growth during the forecast period can be attributed to the increasing prevalence of chlamydia, heightened public awareness, a growing number of point-of-care testing solutions, the escalating prevalence of sexually transmitted diseases, and increased investments in research and development. Major trends during this forecast period include a shift towards point-of-care testing methodologies, advancements in molecular diagnostics, an increased focus on preventative healthcare, the integration of artificial intelligence (AI) in diagnostics, and the development of high-throughput screening platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp

Which Major Market Drivers Are Shaping The Future Of The Chlamydia Market?

The rising incidence of sexually transmitted diseases is anticipated to fuel the expansion of the chlamydia market in the future. Sexually transmitted diseases (STDs) are infections transmitted via sexual interaction, encompassing conditions such as chlamydia, gonorrhea, and HIV. This increase in STDs stems from elements like reduced condom utilization, insufficient public understanding, restricted healthcare accessibility, and the widespread use of dating applications that encourage numerous sexual relationships. Treating chlamydia aids in curbing the dissemination of STDs by eradicating the infection, averting subsequent health issues, and diminishing the likelihood of passing it to partners. An example provided in June 2024, based on data from the National Association of County and City Health Officials, a US non-profit organization, indicates that in 2022, the U.S. recorded more than 2.5 million instances of syphilis, gonorrhea, and chlamydia. During this period, syphilis cases surged by 80%, and congenital syphilis cases escalated by 937%. Specifically, 3,755 congenital syphilis cases were documented, representing a 31% jump between 2021 and 2022. Consequently, the growing occurrence of sexually transmitted diseases is propelling the expansion of the chlamydia market.

What Are The Segment Types Shaping The Chlamydia Market?

The chlamydiamarket covered in this report is segmented –

1) By Test Type: Culture Tests; Nucleic Acid Amplification Test (NAAT); Direct Fluorescent Antibody Test; Serology Tests; Other Test Types

2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration

3) By End User: Hospitals; Diagnostic Centers; Ambulatory Surgical Centers; Other End Users

Subsegments:

1) By Culture Tests: Urethral Swab Culture; Endocervical Swab Culture; Urine Culture Test; Conjunctival Swab Culture

2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction); Transcription-Mediated Amplification (TMA); Strand Displacement Amplification (SDA); Loop-Mediated Isothermal Amplification (LAMP)

3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia; DFA Test For Ocular Chlamydia; DFA For Respiratory Chlamydia Detection

4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA); Immunofluorescence Assay (IFA); Western Blot

5) By Other Test Types: Immunochromatographic Rapid Test; Lateral Flow Immunoassay; Hybrid Capture Test (HCT)

What Are The Major Trends Driving The Growth Of The Chlamydia Market?

Major companies within the chlamydia market are concentrating on developing fully automated instruments to enhance diagnostic precision, reduce human error, and improve the efficiency of testing. A fully automated instrument refers to a system or device that carries out tasks without human involvement, typically employing sensors, control systems, and artificial intelligence for autonomous operation. For instance, in May 2022, BD (Becton, Dickinson and Company), a medical device company based in the US, launched the BD COR MX/PX System. The BD CTGCTV2 molecular assay represents the first test made available on this new system. This single test detects the three most common non-viral sexually transmitted infections (STIs)—chlamydia trachomatis (CT), neisseria gonorrhoeae (GC), and trichomonas vaginalis (TV). These STIs can lead to various negative health outcomes for individuals, including pregnancy complications and a heightened risk of HIV.

Who Are The Core Companies Influencing The Chlamydia Market Landscape?

Major companies operating in the chlamydia market are Pfizer Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Abbott Laboratories, GlaxoSmithKline Plc, Gilead Sciences Inc., Danaher Corporation, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co. Ltd., MedMira Inc., GenMark Diagnostics Inc., Aytu BioScience Inc., ACON Laboratories, Inc., Biocartis Group NV, Inova Diagnostics Inc., Trinity Biotech Plc, Laxai Pharma Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Chlamydia Market?

North America was the largest region in the chlamydia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chlamydia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21138&type=smp

Browse Through More Reports Similar to the Global Chlamydia Market 2025, By The Business Research Company

Sexually Transmitted Infections Stis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sexually-transmitted-infections-stis-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Non Steroidal Anti Inflammatory Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795